Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ritesh Patel

Internal Medicine Schaumburg, IL Medical Doctor

NPI 1548371982 CMS profile 115786

800 E Woodfield Rd, Suite 102, Schaumburg, IL 60173

Open in the dashboard

General payments

$12,866

667 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ritesh Patel of Schaumburg, IL is reported in the CMS Open Payments database as having received $12,866 across 667 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,626 82
2024 General $1,787 70
2023 General $1,282 62
2022 General $1,928 107
2021 General $2,234 108
2020 General $1,946 108
2019 General $2,063 130

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ritesh Patel
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Ritesh Patel were reported at $1,626. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Ritesh Patel Internal Medicine median Middle half National median
2019 $2,063 $159 $48–$570 $163
2020 $1,946 $119 $33–$402 $114
2021 $2,234 $135 $37–$521 $132
2022 $1,928 $141 $42–$496 $149
2023 $1,282 $149 $45–$519 $160
2024 $1,787 $154 $47–$537 $164
2025 $1,626 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $1,869 67 payments
  2. Lilly USA, LLC $1,793 91 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $1,374 91 payments
  4. Janssen Pharmaceuticals, Inc $1,084 65 payments
  5. Novo Nordisk Inc $819 57 payments
  6. Amarin Pharma Inc. $624 33 payments
  7. Amgen Inc. $593 27 payments
  8. GlaxoSmithKline, LLC. $532 32 payments
  9. Pfizer Inc. $511 26 payments
  10. Bayer HealthCare Pharmaceuticals Inc. $488 26 payments
  11. Other $3,178 152 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $12,834 662 payments
  2. Education $32 5 payments
Products named General payments · program years 2019–2025
  1. FARXIGA $1,403 41 payments
  2. XARELTO $935 62 payments
  3. JARDIANCE Diabetes $861 61 payments
  4. JARDIANCE Diabetes $849 45 payments
  5. TRULICITY $811 47 payments
  6. Ozempic $670 49 payments
  7. MOUNJARO $647 30 payments
  8. BREZTRI $515 9 payments
  9. Kerendia $488 26 payments
  10. Vascepa $469 29 payments
  11. Other $8,242 431 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 81 drugs

Part D claims

4,129

Median for Internal Medicine: 777

Drug cost

$673,764

Median for Internal Medicine: $73,373

Branded share of claims

22%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 117 $131,642
Januvia Sitagliptin Phosphate Brand 93 $93,925
Farxiga Dapagliflozin Propanediol Brand 89 $91,472
Trulicity Dulaglutide Brand 47 $73,966
Mounjaro Tirzepatide Brand 46 $56,560
Ozempic Semaglutide Brand 18 $30,025
Prolia Denosumab Brand 16 $27,681
Eliquis Apixaban Brand 17 $21,561
Vascepa Icosapent Ethyl Brand 26 $19,582
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 20 $18,479

The 10 drugs with the highest cost, of 81 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 106 billing codes

Paid by Medicare

$240,220

Of which drugs: $5,852

Medicare patients

441

Average age 74

Services billed

4,018

227 women, 214 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 49%
Arthritis 47%
Ischemic heart disease 39%
Chronic kidney disease 31%
Heart failure 26%
Atrial fibrillation 23%
Osteoporosis 22%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Influenza vaccine, trivalent derived from cell cultures 90661 Office 47 47 $1,690
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 24 34 $31

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 29 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
FARXIGA
  • AstraZeneca Pharmaceuticals LP $200
$200 89 —
Korlym
  • Corcept Therapeutics $162
$162 — —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $81
  • Lilly USA, LLC $56
$136 117 —
Kerendia
  • Bayer HealthCare Pharmaceuticals Inc. $100
$100 — —
SUBLOCADE
  • Indivior Inc. $94
$94 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 29 with Patron

Records

667 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record